The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?

J. Rich*, M. M. Hoeper

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

7 Scopus citations

Abstract

Among the most commonly used therapies to treat pulmonary arterial hypertension (PAH) are the prostanoids. Epoprostenol, a relatively effective therapy for PAH, has its limitations, which are largely attributable to its pharmacokinetic properties and its requirement for intravenous administration. The development of an equally effective oral prostanoid would be an important advance in the PAH armamentarium. An early generation oral prostanoid, beraprost, was previously demonstrated to have modest, transient clinical benefits, but at the cost of a high proportion of intolerable side effects. TRK-100STP is a newer generation oral prostanoid currently under clinical investigation.

Original languageEnglish (US)
Pages (from-to)17-18
Number of pages2
JournalInternational Journal of Clinical Practice
Volume63
Issue numberSUPPL. 161
DOIs
StatePublished - Mar 1 2009

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?'. Together they form a unique fingerprint.

Cite this